Moderna & Merck’s mRNA Cancer Vaccine Secures EMA PRIME Designation

A total of four investigational products targeting unmet medical needs have made it onto the European Medicines Agency’s priority medicines scheme so far this year.

Thumbs up
New applications for entry onto the PRIME scheme get the thumbs up • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards